Regeneron Pharmaceuticals (REGN) is returning from the Thanksgiving break with a hole in its drug research pipeline following the failure of the experimental eye drug nevascumab.

Across two mid-stage clinical trials, the addition of nevascumab to Eylea, Regeneron’s flagship product, failed to improve vision compared to Eylea alone, the company said Monday. The two studies were conducted in patients with diabetic macular edema and wet age-related macular degeneration. Based on these results, Regeneron and its development partner Bayer will not conduct phase 3 clinical trials of nevascumab.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy